

# Andrzej S Krolewski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3211889/publications.pdf>

Version: 2024-02-01

48  
papers

6,106  
citations

147726

31  
h-index

233338

45  
g-index

48  
all docs

48  
docs citations

48  
times ranked

6169  
citing authors

#	ARTICLE	IF	CITATIONS
1	The changing natural history of nephropathy in type 1 Diabetes. American Journal of Medicine, 1985, 78, 785-794.	0.6	795
2	Regression of Microalbuminuria in Type 1 Diabetes. New England Journal of Medicine, 2003, 348, 2285-2293.	13.9	719
3	Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nature Genetics, 1999, 23, 323-328.	9.4	551
4	Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 507-515.	3.0	388
5	Blood Kidney Injury Molecule-1 Is a Biomarker of Acute and Chronic Kidney Injury and Predicts Progression to ESRD in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 2177-2186.	3.0	341
6	Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2007, 18, 1353-1361.	3.0	325
7	Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 516-524.	3.0	307
8	A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nature Medicine, 2019, 25, 805-813.	15.2	260
9	Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria. Diabetes Care, 2014, 37, 226-234.	4.3	219
10	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney International, 2014, 85, 1214-1224.	2.6	182
11	Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2015, 38, 954-962.	4.3	176
12	Risk for ESRD in Type 1 Diabetes Remains High Despite Renoprotection. Journal of the American Society of Nephrology: JASN, 2011, 22, 545-553.	3.0	166
13	Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney International, 2017, 91, 1300-1311.	2.6	159
14	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.3	136
15	High-Normal Serum Uric Acid Is Associated with Impaired Glomerular Filtration Rate in Nonproteinuric Patients with Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 706-713.	2.2	130
16	The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney International, 2012, 82, 589-597.	2.6	120
17	Role of Podocyte B7-1 in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1415-1429.	3.0	114
18	Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney International, 2015, 87, 812-819.	2.6	103

#	ARTICLE	IF	CITATIONS
19	The Genetic Landscape of Renal Complications in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 557-574.	3.0	101
20	Markers of early progressive renal decline in type 2 diabetes suggest different implications for aetiological studies and prognostic tests development. <i>Kidney International</i> , 2018, 93, 1198-1206.	2.6	88
21	Circulating TGF- $\beta$ 1 Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes. <i>Diabetes</i> , 2015, 64, 3285-3293.	0.3	85
22	Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes. <i>Diabetes</i> , 2018, 67, 1013-1023.	0.3	73
23	Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes. <i>Diabetes Care</i> , 2012, 35, 2311-2316.	4.3	61
24	Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. <i>Kidney International</i> , 2016, 89, 226-234.	2.6	57
25	Genetic susceptibility to nephropathy in insulin dependent diabetes: From epidemiology to molecular genetics. <i>Diabetes/metabolism Reviews</i> , 1995, 11, 287-314.	0.4	48
26	Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 2262-2269.	4.3	46
27	Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria. <i>Diabetes Care</i> , 2014, 37, 2601-2608.	4.3	43
28	Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1136-1144.	2.2	41
29	Improved Glycemic Control and Risk of ESRD in Patients with Type 1 Diabetes and Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2916-2925.	3.0	39
30	Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. <i>Kidney International</i> , 2017, 92, 258-266.	2.6	38
31	Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. <i>Diabetes Care</i> , 2019, 42, 93-101.	4.3	37
32	Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria. <i>Diabetes Care</i> , 2020, 43, 2760-2767.	4.3	21
33	Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2331-2351.	3.0	20
34	Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 571-583.	0.7	18
35	Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E876-E882.	1.8	18
36	Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	18

#	ARTICLE	IF	CITATIONS
37	Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. <i>Kidney International</i> , 2022, 102, 370-381.	2.6	17
38	A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders. <i>Kidney International</i> , 2021, 99, 725-736.	2.6	11
39	Mutation Screening of the Neurogenin-3 Gene in Autosomal Dominant Diabetes1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2320-2322.	1.8	9
40	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2634-2651.	3.0	9
41	Molecular characterization of a DDEI melting polymorphism at the angiotensin I-converting enzyme (ACE) locus. <i>Human Mutation</i> , 1994, 4, 155-157.	1.1	6
42	High Risk of ESRD in Type 1 Diabetes: Call for Action: Introduction. <i>Seminars in Nephrology</i> , 2012, 32, 405-406.	0.6	4
43	Comments on Plasma Fibrinogen Levels Measured by Functional Methods. <i>Thrombosis and Haemostasis</i> , 1994, 72, 985-985.	1.8	3
44	Effect of TNF $\alpha$ stimulation on expression of kidney risk inflammatory proteins in human umbilical vein endothelial cells cultured in hyperglycemia. <i>Scientific Reports</i> , 2021, 11, 11133.	1.6	2
45	Four RSAI restriction fragment melting polymorphisms in the region of the insulin receptor gene encoding for the alpha subunit. <i>Clinical Genetics</i> , 2008, 44, 279-280.	1.0	1
46	Ticlopidine May Reduce Functional Fibrinogen Levels by Inhibition of MPC Incorporation into Fibrin. <i>Thrombosis and Haemostasis</i> , 1997, 77, 603-604.	1.8	1
47	A database of naturally occurring human urinary peptides and proteins for use in clinical applications. <i>Nature Precedings</i> , 2007, , .	0.1	0
48	New Frontiers: Approaches to Understand the Mechanistic Basis of Renal Toxicity. <i>Toxicologic Pathology</i> , 2018, 46, 1002-1005.	0.9	0